What Eyerising International Pty Ltd does

Eyerising International Pty Ltd is an Australian medical technology company headquartered in South Yarra, Melbourne, that develops and distributes a myopia management device for children aged 3 to 16. The core product is a compact home-use device that delivers patented Repeated Low-Level Red-Light (RLRL) therapy via a laser diode, administered in 3-minute sessions twice daily for 5 days per week, intended to slow axial elongation and myopia progression under clinical supervision. The offering is complemented by a cloud-based Online Monitoring System that lets clinicians track patient compliance, session data, safety, and progress in real time, and by the Willow Companion Program, a child-facing engagement tool (physical plush plus on-screen character) designed to improve adherence.

The business operates a B2B2C distribution model in which the device is sold exclusively through certified optometrists and ophthalmologists who prescribe it to patients for home use, supported by a global distributor network spanning more than 40 countries across Europe, the Middle East, Asia-Pacific, and Latin America. Revenue is generated through hardware device sales to clinicians; pricing is not publicly disclosed and prospective customers are routed through the company's clinic finder or direct sales contact. The company holds CE marking, ARTG 412752 registration in Australia, ISO 13485:2016 certification, and country-level approvals across multiple jurisdictions, and cites a clinical evidence base of more than 20 trials including up to 87.7% reduction in axial elongation and treatment data covering more than 110,000 individuals.

The company was co-founded by Professor Mingguang He (a world-leading ophthalmology researcher and inventor of the RLRL technology, serving as Founder & CMO) and Jason Sun (Founder & Managing Director), with Michael Woods as Chairman & CFO. It is privately held, operates with 1-10 employees, and has no disclosed external funding rounds. Recent strategic activity has focused on expanding geographic distribution, securing independent safety endorsements in response to published safety concerns, and broadening the product ecosystem through the Willow companion and Online Monitoring System.

Name

Eyerising International Pty Ltd

Legal name

Eyerising International Pty Ltd

Website

https://eyerisinginternational.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Eyerising International is an Australian MedTech company that sells a patented home-use Repeated Low-Level Red-Light (RLRL) therapy device for myopia management in children aged 3-16, distributed exclusively through certified optometrists and ophthalmologists across 40+ countries.

Ownership category

akta.pro rank

Product category

Ophthalmic Medical Devices

NAICS

Ophthalmic Goods Manufacturing (339115), Ophthalmic Goods Merchant Wholesalers (42346)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Refractive Surgery Systems (Excimer/Femtosecond Lasers, Phakic IOL Systems, Wavefront/Guidance) (HLAHAJAG)

akta.pro secondary industry

Contact Lens Specialty & Myopia Control (HLAKAKAK)

Keywords

• Myopia management devices
• Ophthalmic medical devices
• Red-light therapy
• Pediatric eye care
• Medical device manufacturing

Headquarters

HQ city

Melbourne

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

1. Medical Device Sales: The Eyerising Myopia Management Device is sold to eye care professionals (optometrists and ophthalmologists) who then provide it to patients for home use. Revenue is generated through device sales to the clinician network, with ongoing support and monitoring services included.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Eyerising International designs, manufactures, and distributes a patented home-use medical device (the Eyerising Myopia Management Device) that delivers Repeated Low-Level Red-Light (RLRL) laser therapy to slow the progression of myopia in children aged 3–16. The device is prescribed and monitored by optometrists and ophthalmologists, who use a companion cloud-based Online Monitoring System to track patient compliance and progress. The product ecosystem is sold exclusively to eye care professionals and distributed globally through a network of certified clinicians and regional distributors in 40+ countries.

Product overview

Eyerising International offers a unified product ecosystem centered on the Eyerising Myopia Management Device, a patented RLRL therapy device for childhood myopia. The ecosystem comprises the core device (delivering 3-minute red light therapy sessions), the Online Monitoring System (cloud-based clinician dashboard for real-time compliance tracking and patient management), and the Willow companion program (child-facing engagement tool with physical plush and on-screen guidance). Dedicated Customer Support completes the offering. The product is available exclusively through optometrists and ophthalmologists for home use under clinical supervision.

Differentiator

Problem solved

Functional benefit

Products and services

• Eyerising Myopia Management Device A compact, non-invasive home-use medical device that delivers patented Repeated Low-Level Red-Light (RLRL) therapy via a laser diode to help slow axial elongation and myopia progression in children aged 3–16. Treatment is administered in 3-minute sessions twice daily, 5 days per week, prescribed by optometrists or ophthalmologists and used at home under clinical supervision.
• Online Monitoring System A secure, cloud-based platform that gives clinicians real-time visibility into patient treatment compliance, session data, safety, and progress from anywhere in the world. The system automatically records every treatment session and supports adverse event reporting and communication between clinicians and families.
• Willow Companion Program A child-engagement companion offering consisting of a Willow plush character bundled with each device and on-screen animated guidance during treatment. The program provides age-appropriate guidance, reminders, and positive reinforcement during RLRL sessions to improve pediatric adherence.

Quantifiable outcome

• Up to 87.7% reduction in axial elongation reported in clinical studies
• +3 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered major and core.

• Seibersdorf Labor GmbHmajorStrategic or Co-development Partner · 12 August 2026Independent expert evaluation by Dr Karl Schulmeister of Seibersdorf Labor GmbH reviewed the IEC 60825:1-2014 laser safety standard alongside the EMMD treatment protocol to assess safety profile for repeated retinal exposure.
• Academic and Clinical Research Institutions (Asia, Europe, Australia)coreStrategic or Co-development PartnerOngoing clinical trials and research collaborations with academic and clinical partners across Asia, Europe, and Australia. Studies investigate RLRL as standalone and adjunctive therapy, with peer-reviewed publications reporting favorable efficacy and safety outcomes.
• Australian College of OptometrycoreStrategic or Co-development PartnerCollaboration on the ACO Landmark Clinical Trial investigating RLRL therapy. Eyerising is sponsoring a CPD event at the Australian College of Optometry to educate clinicians about RLRL therapy and clinic integration.
• Professor John Marshall (UCL)majorStrategic or Co-development PartnerEmeritus Professor of Ophthalmology at University College London conducted independent safety review of the EMMD device with Dr Karl Schulmeister, concluding the device operates well below retinal injury thresholds.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Emerging players

• Kubota Vision: Kubota Vision develops emKutoBL and related myopia management device approaches based on active stimulation technology. Comparable as a smaller, R&D-stage competitor exploring device-based paediatric myopia interventions with a different optical mechanism.

Direct peers

• SightGlass Vision: SightGlass Vision develops Diffusion Optics Technology (DOT) spectacle lenses for slowing myopia progression in children, now part of CooperVision. Competes in the same paediatric myopia management category with a different mechanism.
• HOYA Corporation (MiYOSMART): MiYOSMART is a clinically validated myopia control spectacle lens using D.I.M.S. technology, sold through optometrists globally for children. It directly competes for paediatric myopia management prescriptions alongside Eyerising's RLRL therapy.
• CooperVision (MiSight): CooperVision's MiSight 1 day is the first FDA-approved contact lens for myopia control in children, targeting the same paediatric myopia management segment as Eyerising via a different modality. It is the benchmark pharmaceutical/device-grade myopia management solution competing for the same clinician prescribing decisions.
• EssilorLuxottica (Stellest): Essilor Stellest lenses with H.A.L.T. technology are a leading myopia management spectacle lens marketed through optometrists worldwide. Competes head-to-head for inclusion in clinician myopia management protocols alongside Eyerising RLRL therapy.
• Beijing Achieve Tech (formerly Sky-n1201a): Chinese manufacturer of RLRL red-light therapy devices for myopia control, including the Sky-n1201a cited in JAMA Ophthalmology safety analyses. Most direct technology competitor in the emerging RLRL category.
• Johnson & Johnson Vision (Abiliti): Johnson & Johnson Vision's Acuvue Abiliti 1-Day is a myopia management soft contact lens system targeting the same paediatric population. Direct competitor for clinician mind-share in paediatric myopia intervention.

Broad incumbents

• Carl Zeiss Meditec: Carl Zeiss Meditec is a leading ophthalmic device and refractive surgery incumbent with global clinical reach. Comparable as a manufacturer of ophthalmic technology used in eye care practices; represents potential adjacent competitive or partnership overlap.
• Topcon Healthcare: Topcon Healthcare supplies ophthalmic diagnostic and refractive devices used by optometrists and ophthalmologists globally. Comparable as a tech-enabled vendor to the same clinician channel that prescribes Eyerising's device.
• Bausch + Lomb: Bausch + Lomb is a global vision care incumbent with ophthalmic pharmaceuticals, contact lenses and surgical products. Its myopia-related R&D and broad optometry channel relationships make it an indirect competitive threat as it expands into paediatric myopia management.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/eyerising-international

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eyerising International Pty Ltd